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A family of endogenous lipids, structurally analogous to the endogenous cannabinoid,
N-arachidonoyl ethanolamine (Anandamide), and called N-acyl amides have emerged as
a family of biologically active compounds at TRP receptors. N-acyl amides are constructed
from an acyl group and an amine via an amide bond. This same structure can be modified
by changing either the fatty acid or the amide to form potentially hundreds of lipids.
More than 70 N-acyl amides have been identified in nature. We have ongoing studies
aimed at isolating and characterizing additional members of the family of N-acyl amides
in both central and peripheral tissues in mammalian systems. Here, using a unique
in-house library of over 70 N-acyl amides we tested the following three hypotheses: (1)
Additional N-acyl amides will have activity at TRPV1-4, (2) Acute peripheral injury will drive
changes in CNS levels of N-acyl amides, and (3) N-acyl amides will regulate calcium in
CNS-derived microglia. Through these studies, we have identified 20 novel N-acyl amides
that collectively activate (stimulating or inhibiting) TRPV1-4. Using lipid extraction and
HPLC coupled to tandemmass spectrometry we showed that levels of at least 10 of these
N-acyl amides that activate TRPVs are regulated in brain after intraplantar carrageenan
injection. We then screened the BV2 microglial cell line for activity with this N-acyl amide
library and found overlap with TRPV receptor activity as well as additional activators of
calcium mobilization from these lipids. Together these data provide new insight into the
family of N-acyl amides and their roles as signaling molecules at ion channels, in microglia,
and in the brain in the context of inflammation.
Keywords: lipid signaling, endocannabinoids, N-acyl amides, TRP receptors, microglia
INTRODUCTION
Transient receptor potential channels (TRPs) form a large fam-
ily of ubiquitous ligand-gated non-selective cation channels that
function as cellular sensors and in many cases regulate intracellu-
lar calcium. Identification of the endogenous ligands that activate
the majority of TRP receptors is still under intense investigation
with most of these channels still remaining “orphans” (Vriens
et al., 2004; Nilius and Owsianik, 2011; Beech, 2012). Much work
has shown that TRPs respond to a variety of external stimuli (e.g.,
plant-derived lipids), however, most TRP receptors are expressed
in areas that would not come in direct contact with external stim-
uli (e.g., CNS tissue, internal organs, smooth muscle); therefore,
the mechanism of direct activation by cellular messengers is still
under much debate and research. In the few cases where endoge-
nous ligands have been identified that drive direct activation of
TRPs, themajority of these ligands are small lipidmolecules, most
of which share structural homology (Bradshaw et al., 2013).
Members of the TRPV family that consists of TRPV1-6,
of which TRPV1-4 (also known as the thermoTRPs for their
responses to heat) are the most targeted TRP receptors for drug
discovery as they are major players in mechanisms of pain and
inflammation (Di Marzo et al., 2002; Julius, 2013). TRPV1 (for-
merly VR1) receptors identification in dorsal root ganglia (DRG)
in 1997 was shown to be a molecular integrator of different types
of noxious stimuli (Caterina et al., 1997). TRPV1 receptors are
mainly expressed in neuronal tissue such as Aδ and C fibers as
well as DRG, trigeminal and nodose ganglia, and sensory neurons
of the jugular ganglia as well as many brain areas (Tominaga et al.,
1998; Caterina and Julius, 2001; Nagy et al., 2004; Starowicz et al.,
2008; Cavanaugh et al., 2011a,b). Yet the complete picture of the
role of TRPV activity in the CNS is still largely unknown and less
still is known about brain TRP activity in the context of pain and
inflammation in the brain. Unlocking the mysteries of TRP chan-
nel activation will have far-reaching effects on our understanding
of cell signaling and pathophysiology in the CNS.
Lipidomics, the field of study focused on identifying and char-
acterizing the full complement of biological lipids, has identified
a class of endogenous lipids, N-acyl amides, which are providing
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a novel avenue from which to studying cellular communication.
N-arachidonoyl ethanolamine, (Anandamide—the first endoge-
nous cannabinoid identified) is an archetypeN-acyl amide that is
constructed from an acyl group, arachidonic acid, and an amine,
ethanolamine via an amide bond. This same structure can be
modified by changing either the fatty acid or the amide to form
potentially hundreds of lipids (Figure 1). More than 70 N-acyl
amides have been identified in nature and our group has been a
driving force behind this work (Bradshaw and Walker, 2005; Tan
et al., 2006; Burstein et al., 2007; Hu et al., 2008; Rimmerman
et al., 2008; Bradshaw et al., 2009; Hu et al., 2009; Lee et al.,
2010; Mchugh et al., 2010; Smoum et al., 2010; Tortoriello et al.,
2013).
Multiple members of the N-acyl amide class of lipids have
been shown to activate a member of the TRPV family (Di Marzo
et al., 2002; Julius, 2013). Anandamide was the first N-acyl
amide shown to activate TRPV1 channels (Zygmunt et al., 1999).
N-arachidonoyl dopamine (NADA) and N-oleoyl dopamine
(OLDA), which are structurally similar to the exogenous TRPV1
agonist capsaicin as well as N-acyl amide structural analogs to
AEA, are more potent endogenous ligand for TRPV1 receptors
(Huang et al., 2002; Chu et al., 2003). Additional work showed
that N-arachidonoyl taurine, which does not activate CB recep-
tors, actives both TRPV1 and TRPV4 receptors (Saghatelian et al.,
2006). Likewise, a broader range of N-acyl ethanolamides were
shown to activate TRPV1 (Movahed et al., 2005), further demon-
strating that non-eCB type N-acyl amides could also activate
TRPs.
Here, we used a unique in-house library of over 70 N-acyl
amides (for complete listed see Supplemental Table 1) we tested
the following three hypotheses: (1) AdditionalN-acyl amides will
have activity at TRPV1-4, (2) Acute peripheral injury will drive
changes in CNS levels of N-acyl amides, and (3) N-acyl amides
will regulate calcium in CNS-derived microglia. Through these
studies we identified 20 novel N-acyl amide activators of these
TRPVs collectively. We then performed targeted lipidomics using
the N-acyl amide library on 6 brain regions to determine if acute
inflammation by intraplantar paw injection of carrageenan would
drive changes in these lipids. Here, we demonstrated that a wide
range of lipids are regulated in the brain during acute inflam-
mation and at least 10 of these newly identified TRPV activator
lipids are regulated in the brain at 3 h post injection suggesting
that this family of lipids plays important roles in CNS signaling.
Finally, we screened BV2 microglial cells with the N-acyl amide
library to determine if N-acyl amides play a role in microglial
signaling. In these experiments we show that 6 novel N-acyl
amide families of lipids active these microglial cells, 5 of which
had members that were upregulated 3 h post-carrageenan injec-
tion in the brain. Data presented here provide evidence that the
TRPV and N-acyl amide systems may work together to respond
to rapid changes in the neurophysiological environment of acute
pain.
MATERIALS AND METHODS
CHEMICALS
Fura-2 AM was purchased from Invitrogen (Carlsbad, CA). 5-
Iodoresiniferatoxin (I-RTX) was purchased from Tocris Cookson
Inc. (Ellisville, MO). Ruthenium red was purchased from Sigma-
Aldrech (St. Louis, MO). 2-Aminoethoxydiphenyl borate (2-
APB) and 4-alpha-Phorbal 12,13-didecanoate (4-alpha PDD)
were purchased from Enzo Life Sciences (Farmingdale, NY). Each
of the following N-acyl amides were purchased from Cayman
Chemical (Ann Arbor, MI): N-arachidonoyl ethanolamine
(Anandamide; AEA), N-oleoyl ethanolamine (OEA), N-palmitoyl
ethanolamine (PEA), N-linoleoyl ethanolamine (LEA), N-
docosahexaenoyl ethanolamine (DEA), N-arachidonyl glycine
(NAGly), and 2-AG All other reagent-grade N-acyl amides were
synthesized in house as previously described (Tan et al., 2010).
Unless otherwise indicated, all compounds were stored in 100%
ethanol, however, assay solutions were made fresh in DMSO
prior to every assay. Chemicals used for mass spectrometry were
HPLC-grade and include methanol, water, ammonium acetate,
and acetic acid. HPLC water and methanol were purchased from
VWR International (Plainview, NY). Ammonium acetate and
acetic acid were purchased from Sigma Aldrish (St. Louis, MO).
ANIMALS
All protocols were approved by the Indiana University
Institutional Animal Care and Use Committee. Adult male
Sprague–Dawley rats (Harlan, Indianapolis, IN USA) were used
in all experiments. Rats were kept 4 to a cage in standard cages
on a 12:12-h light–dark cycle. Food and water were available ad
libitum. All subjects were adapted to the laboratory environment
for a minimum of 2 weeks prior to use in our studies.
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FIGURE 1 | Structure of N-acyl amides. N-acyl amides studied here have a
structure that consists of an acyl group (denoted as R) and an amide bond to
an amine (denoted as R1) and this is depicted as a cartoon structure here (far
left). 4 examples of N-acyl amide bioactive molecules are also depicted:
N-arachidonoyl ethanolamide (Anandamide; AEA); N-arachidonoy glycine
(NAGly); N-palmitoyl ethanolamide (PEA); and N-palmitoyl glycine (PalGly).
These 4 N-acyl amide species illustrate that the molecules can differ by
changing the acyl group (AEA and PEA) or the amide (AEA and NAGly).
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CELL CULTURE
Human embryonic kidney cells (HEK-293) stably expressing
human TRPV1-4 and BV-2 cells were cultured as monolayers in
T-75 flasks and expanded to passages 15–23. Cells were main-
tained in Dulbecco’s minimum essential medium (DMEM)mod-
ified with non-essential amino acids, L-glutamine, and 2.2 g/L
sodium bicarbonate and supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (P/S). Cells were
subcultured an average of three times a week with Trypsin-EDTA
1× and grown at 37◦C in a humidified atmosphere of 5% CO2 in
air; this was done 48 h prior to calcium assays.
CALCIUM (Ca2+) IMAGING ASSAY
The effect of the N-acyl amides on calcium mobilization was
assessed using a high-throughput 96-wells plate assay adapted
from our previous work (Rimmerman et al., 2008). TRPV1
(human), TRPV2 (mouse), TPRV3 (mouse), or TRPV4 (rat)-
transfected HEK-293 (TRPV2 cells were a kind gift from
Vincenzo DiMarco and the TRPV3 and 4 cells were a kind gift
from Michael Caterina) cells were seeded on Cell BIND 96-
well flat clear bottom black polystyrene microplates (Corning
Life Sciences, Acton, MA) coated with 50μg/mL poly-D-Lysine
(PDL) under the cell culture hood at room temperature, allowing
cells to attach to plates. Cells were grown to 75–85% conflu-
ence in a monolayer in the culture medium described above
for 24–48 h. Prior to all experiments, cells were examined under
the microscope to check for optimal confluency and normal
morphology.
AGONIST ACTIVITY CALCIUMMOBILIZATION SCREENS
Prior to loading the cells, the selective intracellular fluorescent
probe for calcium, Fura-2-acetoxymethyl ester (Fura-2AM), was
removed from –20◦C and allowed to equilibrate to room tem-
perature while protected from light. Cells were then loaded
with 3μM Fura-2AM at room temperature for 1 h, in HEPES-
Tyrode buffer containing 0.05% w/v pluronic F-127 (Invitrogen).
HEPES-Tyrode buffer was prepared with HEPES 0.025mol, NaCl
0.14mol, KCl 0.0027mol, CaCl2 0.0018mol, MgCl2 0.0005mol,
NaH2PO4 0.0004mol, and glucose 0.05mol, and HEPES-Tyrode
buffer used in calcium imaging assays was adjusted to pH 7.4 in
order to avoid cellular ionic perturbation. After 1 h of Fura-2AM
incubation, cells were washed twice and incubated in 175μL of
HEPES-Tyrode buffer for 20min at room temperature. The plates
were scanned for calcium activity using Flex Station II (Molecular
Devices, Sunnyvale, CA) at 27◦C. After 30 s of baseline record-
ing, cells were challenged with 75μL of buffer containing N-acyl
amide solutions or positive control agonists capsaicin (TRPV1),
2-APB (TRPV2 and 3), 4α PDD (TRPV4), or PAF (BV2) which
was first dissolved in DMSO or challenge compounds that were
first dissolved in 100% DMSO at different concentrations and
then added to buffer for a final DMSO concentration of 0.5% or
vehicle (DMSO) alone using the automated fluidic module of Flex
Station II.
ANTAGONIST ACTIVITY SCREENS
Similar to the agonist activity assay, cells were incubated at room
temperature for 1 h with 3μM Fura-2AM in HEPES-Tyrode
buffer containing 0.05% w/v pluronic F-127. Cells were then
washed twice and resuspended in 175μL of HEPES-Tyrode buffer
containing the 10μM N-acyl amide mixture or individual com-
pound (depending on the assay) which was first dissolved in 100%
DMSO and added to the buffer to make a final concentration
of DMSO of 0.5%. or vehicle (DMSO) alone and incubated for
20min. These plates were then loaded into the FlexStationII and
following 30 s of baseline recording, the pre-incubated cells were
then challenged with 75μL of HEPES-Tyrode buffer containing
the corresponding positive control agonists capsaicin (TRPV1),
2-APB (TRPV2 and 3), or 4α PDD (TRPV4) which was first
dissolved in DMSO. The plates were then scanned for calcium
activity using Flex Station II (Molecular Devices, Sunnyvale, CA)
at 27◦C. The following positive control antagonists were used to
compare the level of activity of N-acyl amide mixtures or individ-
ual lipids: Iodo-resiniferatoxin (I-RTX; TRPV1), Ruthenium Red
(TRV2-4).
IN VIVO INDUCED PAW INFLAMMATION
Male Sprague–Dawley rats remained in their home cage but
were placed in the testing room for at least 1 h prior to injec-
tion to allow for acclimation to the novel environment. Rats
were divided into two groups. Control groups received a 50μL
intraplantar injection of vehicle (saline) into the right hind paw
and experimentally-treated animals received a 50μl intraplantar
injection of 3% carrageenan (CG) dissolved in saline into the
right hind paw. All solutions of CG or saline were adjusted to
pH 7.4.
PAW INFLAMMATION ASSESSMENT AND TISSUE EXTRACTION
Paw inflammation was evaluated in all animals at 3 h following
carrageenan injection by using calipers to measure dorsal-to-
ventral paw thickness. Rats were euthanized by decapitation and
brains removed, placed in Eppendorf tubes and flash-frozen in
liquid nitrogen. After brains were frozen, they were quickly dis-
sected and the striatum, thalamus, hippocampus, cerebellum,
midbrain and brainstem were placed in individual ependorph
tubes, and flash frozen in liquid nitrogen. Tissue samples were
kept in a −80◦C freezer until used for lipid extraction.
LIQUID CHROMATOGRAPHY/TANDEMMASS SPECTROMETRY
(LC/MS-MS)
Levels of each compound were analyzed by multiple reactions
monitoring (MRM) mode using an applied Biosystems/MDS
Sciex triple quadrupole mass spectrometer API 3000 (Foster
City, CA) with electrospray ionization as previously described
(Bradshaw et al., 2006; Rimmerman et al., 2008; Lee et al., 2010;
Ho et al., 2012; Tortoriello et al., 2013). Samples were loaded
using Shimadzu SCL10Avp auto-sampler and chromatographed
on a 210mm Zorbax Eclipse XDB-C18 reversed-phase HPLC
column (3.5μm internal diameter) maintained at 40◦C. The
flow rate was 200μL/min achieved by a system comprised of a
Shimadzu controller and two Shimadzu LC10ADvp pumps. The
Shimadzu LC10ADvp HPLC pumps operated with a starting gra-
dient of 0% mobile phase B which was increased to 100% before
returning back to 0%. The mobile phase A consisted of 20/80
MeOH/water containing 1mM ammonium acetate and mobile
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phase B consisted of 100% MeOH containing 1mM ammonium
acetate and 0.5% acetic acid.
DATA ANALYSIS
The analysis of calcium imaging experiments using 96-wells plate
was as follows: after 30 s of baseline recording, cells were chal-
lenged with the drug, and calcium data per each well was collected
every 5 s for a total scan time of 200 s and then calculated as the
area under the curve (in relative florescence units) using Softmax
Pro 5 integration functions (Molecular Devices, Union City, CA).
Levels of calcium flux per each treatment group were collected
from all repeats and data are presented as mean ± standard error
of the mean (SEM) from at least three different experiments.
Graph Pad Prism was used for further statistical analysis. Results
were analyzed using One-Way ANOVA with Bonferroni’s (cal-
cium imaging data) or Fishers LSD (lipidomics) post hoc tests.
EC50 are calculated by non-linear regression analysis using the
equation for sigmoidal concentration-response curve in Graph
Pad Prism 4.0. ∗p-value of p < 0.05 or #p-value of p < 0.01 are
considered significant.
The 340/380 fluorescence intensity ratio of Fura2AM emission
was collected every 5 s for a total scan time of 200 s. Calcium flux
per each well was calculated as the area under the curve in relative
fluorescence units using Softmax program integration functions.
Graph Pad Prism was used for further statistical analysis. The
number of repeats per each treatment group varies between 5
and 10 from at least three independent experiments. The major-
ity of mixtures of N-acyl amides caused calcium mobilization
that was significantly different from vehicle alone when analyzed
with an alpha level of p < 0.05, however, the effect size was of
a low magnitude. In an attempt to narrow down those groups
that had the greatest magnitude effect, we set the alpha level to
P < 0.01.
HPLC/MS-MS data was analyzed as previously described
(Bradshaw et al., 2006; Rubio et al., 2007; Rimmerman et al.,
2008; Lee et al., 2010; Tan et al., 2010). In brief, the detection
of each analyte was based on fragmentation of the precursor ion
to yield a daughter ion in the negative ion mode with MRM.
The retention times of each of the analyzed compounds were
compared to those obtained from their corresponding standards.
The area under the curve for the appropriate compound was
obtained. The amount of each compound was extrapolated from
a calibration curve obtained from analyzing known concentra-
tion of synthetic standards and then corrected based up on the
extraction efficiency. Final expression of total amounts are in
mols/gram tissue (wet wt.). ANOVA analyses were made between
1 h post vehicle and carrageenan injection or 3 h post vehicle
or carrageenan injection treatment groups. Individual ANOVAs
were performed for each individual lipid family in that there was
no a priori assumption that any one lipid specie would have
an effect on another, nor would there be interactions between
them.
RESULTS
CALCIUMMOBILIZATION OF N-ACYL AMIDE FAMILIES AT TRPV1-4
The first set of experiments were aimed at screening mix-
tures of each of the N-acyl amide families from our unique
library of compounds in each of the TRPV-HEK expression
systems. Supplemental Table 1 identifies the complete list of
compounds used in the screen and they are grouped as a struc-
tural “family” from the categorization of the amine as the
grouping mechanism. As an example, all those N-acyl glycine
molecules that are in the library are considered a unique “fam-
ily” of compounds and a mixture of each at the same molar-
ity was used as a single screening tool in each of the trans-
fected cell lines. Each of the TRPV1-4 expression systems tested
had at least one positive hit with an N-acyl amide mixture
(Table 2). For agonist activity 4 different families drove cal-
cium in TRPV1-HEK cells, TRPV2 had 2, TRPV3 had 1, and
TRPV4 had 2. Whereas, none of the novelN-acyl amide mixtures
induced calcium mobilization in non-transfected HEK-293 cells
(Table 1).
CALCIUMMOBILIZATION OF INDIVIDUAL N-ACYL AMIDES IN TRPV1-4
HEK EXPRESSION SYSTEMS
In a second level of analysis, each individual member of the
N-acyl amide mixtures that stimulated calcium mobilization
in the first screen was tested separately in the same TRPV1-
4 HEK/Fura-2AM system. Figure 2 shows an example case of
individual N-acyl GABA compounds being screened in the
TRPV1-HEK system. These experiments with the N-acyl GABAs
showed a structure-activity relationship for N-docosahexaenoyl
GABA (D-GABA), N-linoleoyl GABA (L-GABA), and N-
arachidonoyl GABA (A-GABA) all causing significant calcium
mobilization; therefore we extended the analysis to include
full concentration curves for all N-acyl-GABAs. D-GABA,
L-GABA, and A-GABA significantly induced concentration-
dependent activation of TRPV1 and that each reached an
asymptote equivalent to NADA (Figure 2A). Similar to NADA,
D-GABA, L-GABA, and A-GABA induced an immediate, sus-
tained increase of calcium (Figure 2B). Supplementary Figures
1–6 show additional data on individual N-acyl amide activ-
ity in TRPV1-4 HEK systems. These data revealed an addi-
tional 5 N-acyl amides at TRPV1 (N-docosahexaenoyl serine,
N-docosahexaenoyl glycine, N-docosahexaenoyl aspartic acid,
N-docosahexaenoyl ethanolamide, N-linoleoyl ethanolamide),
1 at TRPV2 (N-palmitoyl tyrosine), none above the statistical
threshold at TRPV3 and 6 at TRPV4 (N-arachidonoyl tyrosine,
N-linoleoyl tyrosine, N-palmitoyl tyrosine, N-docosahexaenoyl
tryptophan, N-arachidonoyl tryptophan, N-linoleoyl trypto-
phan). These findings are summarized as a cartoon in
Figure 3.
ANTAGONIST ACTIVITY AT TRPV1-4 BY N-ACYL AMIDES
N-acyl amide mixtures listed in Supplemental Table 1 were
screened as antagonists at TRPV1-4. As with the agonist screens,
we used a known antagonist for each of the TRPV expression
systems as our antagonist positive control and challenged the
TRPV-HEK expression systems with the same known agonist as
in the agonist screens (see Materials and Methods for list of com-
pounds used). Table 2 shows the positive hits for each TRPV
expression system. The majority are those that also showed ago-
nist activity also showed antagonist activity (e.g., N-acyl GABA
mixture is a strong agonist/antagonist at TRPV1), which suggests
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Table 1 | Agonist activity of N-acyl amides at TRPV1-4.
Agonist activity
N-acyl amides Non-transfected TRPV1 TRPV2 TRPV3 TRPV4
(10 μM mixtures) HEK-293
N-acyl alanine 7.88±3.50 16.71±0.81 45.74±5.58 14.89±2.19 30.13± 3.94
N-acyl aspartic acid 11.97±4.60 95.13 ± 10.24 6.41±0.79 26.72±4.11 25.58± 6.19
N-acyl beta-alanine 5.16±3.76 22.78±1.34 23.88±5.21 21.18±1.71 9.35± 3.29
N-acyl GABA −8.15±4.21 153.08 ± 10.25 23.58±5.13 20.24±2.76 16.00± 2.97
N-acyl glycine −20.47±8.29 85.61 ± 16.80 22.10±5.43 12.14±2.98 32.03± 4.23
N-acyl isoleucine −9.52±3.25 20.20±2.71 31.16±7.62 9.83±2.23 17.37± 4.39
N-acyl leucine 2.78±1.79 10.00±1.92 16.99±2.19 −2.00±0.32 4.20± 1.83
N-acyl methionine −10.34±4.65 17.02±2.04 30.67±5.03 28.65±4.82 30.46± 4.97
N-acyl phenylalanine −15.04±3.00 0.68±1.75 −5.90±1.45 −7.55±1.22 24.13± 3.54
N-acyl proline −8.21±2.41 28.34±5.73 73.35 ± 2.20 23.92±3.72 23.84± 4.95
N-acyl serine −9.98±6.27 128.76 ± 29.90 2.87±2.46 20.56±1.96 6.28± 1.76
N-acyl threonine −0.47±2.52 19.40±1.01 1.57±1.37 12.66±1.05 20.40± 2.27
N-acyl tryptophan 11.39±2.55 19.33±2.81 3.94±1.18 13.46±1.49 75.59 ± 7.79
N-acyl tyrosine −13.72±5.83 39.05±2.61 74.78 ±15.21 43.61± 2.42 55.59 ± 7.79
N-acyl valine −5.14±4.69 26.63±3.63 9.01±1.70 13.42±3.79 23.86± 4.27
DMSO −5.46±2.93 8.10±0.75 −1.59±1.68 −0.78±1.36 2.14± 0.98
Capsaicin (10μM) 294.67 ± 31.31
NADA (10μM) −11.92±2.74 220.14 ± 25.25
2-APB 238.24 ± 13.38 121.6± 3.48
4α-PDD 76.92 ± 10.99
Far left column lists the N-acyl amide family or control compound that was used as the challenge compounds for each screen. Subsequent columns contain the data
from each individual TRPV-HEK expression system as well as the untransfected HEK cells. Values shown are the change in relative fluorescence units of Fura2AM
from the 30 s baseline and represent the area of the curve of analysis of 190 s post injection (see example on Figure 2). The overwhelming majority of N-acyl
amide mixtures caused significant increases in baseline calcium at p = 0.05 levels over that of the DMSO controls, which were the equivalent to zero. In order to
streamline the screening process, we chose to focus on those differences that were only p ≤ 0.01. Those values in bold black are significantly different from those
of the vehicle injection at p ≤ 0.01.
a likely competitive inhibition. Therefore, we focused our efforts
for identifying antagonists to those hits that did not have any
agonist activity, which singled out the N-acyl proline mixture
at TRPV1 and the N-acyl leucine and N-acyl valine mixtures at
TRPV3.
ANTAGONIST ACTIVITY ON CALCIUMMOBILIZATION OF INDIVIDUAL
N-ACYL AMIDES IN TRPV1 AND TRPV3 HEK EXPRESSION SYSTEMS
Of particular interest in the category of the TRPV1 screen
was the N-acyl proline mixture. This mixture had no ago-
nist activity and a screen of the individual members revealed
that N-docosahexaenoyl proline is a potent TRPV1 inhibitor
(Supplemental Figure 7). Likewise, the N-acyl valine mix-
ture had no agonist activity at TRPV3, however, there were
4 individual N-acyl valine compounds that act as antago-
nists (N-docosahexaenoyl valine, N-linoleoyl valine, N-oleoyl
valine, N-stearoyl valine; Supplemental Figure 8), whereas,
the activity of individual N-acyl leucine species were not
significant. All of the individual N-acyl amides that acti-
vate or inhibit the TRPV1-4 receptors are summarized in
Figure 3.
LIPIDOMICS OF 6 DISTINCT BRAIN REGIONS AFTER PERIPHERAL
INFLAMMATION REVEAL NOVEL ENDOGENOUS N-ACYL AMIDE
REGULATION
To address one potential aspect of functional relevance of N-acyl
amide signaling, we performed a series of targeted lipidomics
screens of 75N-acyl amides via HPLC-MS/MS on 6 distinct areas
of the brain (striatum, hippocampus, cerebellum, thalamus, mid-
brain, and brainstem) in order to survey N-acyl amide regulation
during an acute inflammatory stimulus. Using the intraplantar
carrageenan peripheral inflammationmodel, we induced an acute
inflammatory response and measured changes in brain levels of
N-acyl amides. Supplemental Figure 9 shows that the levels of
edema in the injected paw were significantly greater than vehi-
cle injected at both 1 and 3 h post injection. A majority of all the
lipids measured were detected in each of brain areas surveyed and
each lipid was found in pmol/gram levels (Supplemental Figure
9 shows matching chromatograms from standards and extracts
for 3 N-acyl GABA species; Supplemental Table 2 shows all the
averaged values for each of the lipids detected in each brain area).
Analysis of all lipids in each brain area and comparisons among
the four treatment groups was multi-variant. Given that here
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FIGURE 2 | Individual N-acyl GABA species drive calcium in
TRPV1-transfected HEK cells. (A) Concentration curves of individual
N-acyl GABA: N-docosahexaenoyl GABA (D-GABA), N-arachidonoyl GABA
(A GABA), N-linoleoyl GABA (L GABA), N-oleoyl GABA (O GABA),
N-palmitoyl GABA (P GABA) and N-stearoyl GABA (S GABA) compared to
the potent TRPV1 agonist, N-arachidonoyl dopamine (NADA). (B)
Flourescence intensity that is an indication of calcium mobilization as
measured by the ratiometric calcium-sensitive dye FURA2am in response
to D-GABA, A GABA, L GABA, NADA, and the vehicle, DMSO. Data were
generated in a Flexstation II (Molecular Devices).
were four treatment groups and an n of 8 per treatment group,
mass spectrometric analysis yielded an enormous quantity of data
totaling 14,400 data points for these six brain areas tested (Data
shown in Supplemental Table 2). Here, we provide an example
of the analysis of those measurements in the hippocampus and
striatum.
Out of the 75 spectra analyzed, 48 analytes were detected in
hippocampal samples, whereas 57 were detected in striatal sam-
ples. Two different levels of analyses were performed. The first
level was to compare Veh-1H to CG 1H and then the second level
of analysis was to compare Veh-3H and CG-3H. To simplify the
analysis into more manageable units, we compared only those
lipids within an N-acyl amide family in a single ANOVA. For
example, only N-acyl ethanolamides were compared to the same
N-acyl ethanolamides. Future studies are aimed at using these
data sets in a modeling system to determine if there are predictive
TRPV1
DEA, LEA
AGABA
DGABA, LGABA
DSer , DGly
DAsA
DPro
TRPV2
PTyr SVal
OVal
LVal
DVal
TRPV3
TRPV4
ATyr
LTyr
PTyr
LTryp
A Tryp
DTryp
FIGURE 3 | Composite for all individual N-acyl amides tested here with
activity at TRPV1-4. This cartoon illustrates N-acyl amides that were
shown to be active as agonists (Bold Black; arrow) and antagonists (Bold
Gray; bar) in each of the TRPV1-4 expression systems, which are
represented simply as the individual receptor. Agonists at
TRPV1: N-docosahexaenoyl GABA (DGABA), N-arachidonoyl GABA
(AGABA), N-linoleoyl GABA (LGABA); N-docosahexaenoyl serine (DSer),
N-docosahexaenoyl glycine (DGly), N-docosahexaenoyl aspartic acid
(DAsA), N-docosahexaenoyl ethanolamide (DEA), N-linoleoyl ethanolamide
(LEA); Antagonists at TRPV1: N- docosahexaenoyl proline (DPro); Agonists
at TRPV2: N-palmitoyl tyrosine (PTyr); Antagonists at TRPV3:
N-docosahexaenoyl valine (DVal), N-linoleoyl valine (LVal), N-oleoyl valine
(Oval), N-stearoyl valine (SVal); Agonists at TRPV4: N-arachidonoyl tyrosine
(ATyr), N-linoleoyl tyrosine (LTyr); PTyr; N-docosahexaenoyl tryptophan
(DTryp), N-arachidonoyl tryptophan (ATryp), N-linoleoyl tryptophan (LTryp).
directions of types of N-acyl amides or their fatty acid deriva-
tives in a particular direction, but that is beyond the scope of the
analysis here.
Table 3 summarizes the results of the 34 N-acyl amides that
were shown to be modified at either 1 or 3 h post injection as a
function of each individual brain area. Of the 12 lipids that were
modified (either increasing or decreasing) at the 1 h time point,
6 were in found in the hippocampus and 9 of the 12 significantly
decreased. This is in stark contrast to the changes in the levels
of N-acyl amides in the brain 3 h after carrageenan injections
wherein all the N-acyl amides that were modified by the treat-
ment were significantly higher than those with vehicle injection.
Whereas the most differences measured at 1 h post carrageenan
were in the hippocampus, the area of the brain with the most dra-
matic changes in N-acyl amides at 3 h post carrageenan were in
the striatum and cerebellum. Notably, all brain areas tested had
significant increases in N-acyl ethanolamides and three of the
six (striatum, hippocampus, and cerebellum) all had significant
increases in N-acyl glycines. Of the 34 N-acyl amides that were
up or down regulated with peripheral inflammation, 10 showed
activity at TRPVs in the assays discussed above and are denoted
in gray in Table 3.
CALCIUMMOBILIZATION BY N-ACYL AMIDES IN BV-2 MICROGLIAL
CELLS
Activation and mobilization by microglia occurs not only during
times of mechanical and pathogen-induced tissue damage, but
also in times of acute pain (Ji et al., 2013). To test the hypoth-
esis that N-acyl amides would drive calcium mobilization in
microglia, we screened N-acyl amide mixtures in the microglial
cell line BV2. Table 5 shows that 5 different N-acyl amide fam-
ily mixtures drive calcium mobilization in BV2 cells, whereas 1
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Table 2 | Antagonist activity of N-acyl amides at TRPV1-4.
Antagonist activity
N-acyl amides TRPV1 (+ CAP) TRPV2 (+ 2-APB) TRPV3 (+ 2-APB) TRPV4 (+ 4α-PDD)
(10 μM mixtures)
N-acyl alanine 155.12±10.33 267.43±14.53 74.55±4.34 87.46± 8.03
N-acyl aspartic acid 187.20±11.78 251.09±12.01 65.74±13.38 83.25± 8.34
N-acyl beta-alanine 166.84±13.52 239.05±25.01 92.69±9.95 91.59± 5.26
N-acyl GABA 87.22 ± 11.12 277.24±22.89 163.03±15.23 94.24± 5.71
N-acyl glycine 151.43±10.3 255.01±16.16 123.01±10.80 85.11± 7.15
N-acyl isoleucine 185.08±5.76 285.96±30.44 62.73±3.80 97.22± 5.46
N-acyl leucine 179.18±13.56 235.66±22.26 51.37± 3.10 80.25± 6.18
N-acyl methionine 158.93±14.24 237.28±18.32 65.15±5.74 91.50± 9.87
N-acyl phenylalanine 180.70±10.01 260.15±28.61 75.64±22.64 81.56± 4.54
N-acyl proline 95.98 ± 21.26 −34.61 ± 26.70 142.49±6.48 94.16± 11.34
N-acyl serine 196.28±6.53 234.06±22.36 69.65±5.10 94.83± 5.23
N-acyl threonine 197.53±7.51 210.15±17.10 81.18±5.96 83.89± 7.96
N-acyl tryptophan 201.35±3.26 263.71±24.69 61.91±6.13 −99.49 ± 38.83
N-acyl tyrosine 156.56±15.15 −116.42 ± 13.94 58.78±5.40 −124.36 ±, 22.53
N-acyl valine 174.62±11.94 240.61±26.79 39.73 ± 4.16 37.05± 7.37
DMSO 195.69±16.42 253.67±39.42 95.73±7.01 93.92± 11.55
I-RTX (20 nM) −22.15 ± 5.80
Rethenium red (30μM) 64.83 ± 4.51 41.33 ± 3.75 −85.52 ±, 34.61
Far left column lists the N-acyl amide family or control compound that was used as the pre-incubated compounds for each screen. Challenge compounds are listed
under the title of the TRPV-HEK expression system. Values shown are the data from the change in relative fluorescence units of Fura2AM from the 30 s baseline and
represent the area of the curve of analysis of 190 s post injection of the positive control challenge compound. Those values in bold black are significantly different
from those of the vehicle injection p ≤ 0.01.
mixture (N-acyl phenylalanines) caused a significant depression
of the baseline calcium signaling. We chose one mixture, the N-
acyl GABA lipids to assess activity by individual lipid species.
Supplemental Figure 10 shows that there is a structure activity
relationship in the N-acyl GABA family. Importantly, however,
there was no calcium mobilization by capsaicin (Table 4) sug-
gesting that N-acyl GABA lipids are likely acting through an
alternative receptor.
DISCUSSION
Lipidomics as a field aims to both identify the full complement
of biologically active lipids as well as their functional relevance.
Here, we have combined a bottom–up approach targeting activ-
ity of novel N-acyl amide lipids at specific TRPV1-4 receptors
and BV2 microglia with a top–down approach of screening the
production or metabolism of these lipids in the brain in a model
of peripheral inflammation and pain. Together these approaches
provide a powerful set of tools that enabled us to discover addi-
tional endogenous ligands for TRPV1-4 and microglia as well
as determine how these ligands are regulated in the CNS with
inflammation, thereby generating a novel hypothesis for the acti-
vation and regulation of lipid signaling molecules and their
receptors.
BOTTOM-UP LIPIDOMICS OF N-ACYL AMIDES AT TRPV1-4 AND BV-2
MICROGLIA
TRPV receptor activation and regulation as part of the processing
of nociceptive information in the periphery and the CNS is not
fully understood. Here, we identified 20 novel N-acyl amides
as putative ligands for TRPV1-4 channels. These data add to
the growing literature that activation of TRP channels follows
an opportunistic strategy in which, a wide range of struc-
turally similar endogenous lipids are capable of driving calcium
mobilization through these channels (Movahed et al., 2005;
Bradshaw et al., 2013). An interesting example of this oppor-
tunistic strategy is the evidence here demonstrating that TRPV1
is activated by eight additional novel N-acyl amides, including
N-docosahexaenoyl ethanolamine, which including the previ-
ous work by Movahed et al. (2005) brings the number of lipids
in the N-acyl ethanolamine family alone up to at least 5. One
difference between the two studies was the potency of OEA at
TRPV1, which was higher than 10μM in our hands, therefore,
not further investigated here. However, this discrepancy may be
due to the very different assay conditions between the two stud-
ies. We were able to detect all of these novel TRPV1 agonists
except N-docosahexaeonyl aspartic acid in the brain. These data
support the existing hypothesis that the primary endogenous
TRPV1 ligands are long-chain, unsaturated acyl-amides (e.g.,
AEA; NADA; OLDA) and extends the number of endogenous
N-acyl amide TRPV1 ligands to at minimum 13. Even though
we were unable to test all the individual lipids in our screen at
each of the TRPVs tested here, of those that were individually
screened the vast majority did not activate TRPV1, suggesting
that it is not simply a response to long-chain N-acyl amides
of any structure. This finding replicates an earlier finding that
NAGly and the oxidized AGABA (AGABA-OH) had no activity at
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Table 3 | Effects on N-acyl amide lipidomics profile in 6 brain areas 1 and 3h post carrageenan.
STR HIPP CER THAL MID STEM 
  
1H 3H 1H 3H 1H 3H 1H 3H 1H 3H 1H 3H 
N-acyl alanine                         
N-palmitoyl alanine                 ↓       
N-stearoyl alanine     ↑                   
N-oleoyl alanine     ↓ ↑                 
N-arachidonoyl alanine #     ↓                   
N-docosahexaenoyl alanine  #   ↑                     
N-acyl ethanolamine                         
N-palmitoyl ethanolamine   ↑   ↑   ↑   ↑       ↑ 
N-stearoyl ethanolamine   ↑                     
N-oleoyl ethanolamine   ↑   ↑   ↑ ↓ ↑   ↑   ↑ 
N-linoleoyl ethanolamine   ↑   ↑   ↑   ↑   ↑   ↑ 
N-arachidonoyl ethanolamine   ↑   ↑   ↑   ↑   ↑   ↑ 
N-docosahexaenoyl ethanolamine   ↑   ↑   ↑   ↑         
N-acyl GABA                         
N-palmitoyl GABA           ↑             
N-stearoyl GABA           ↑             
N-oleoyl GABA           ↑             
N-linoleoyl GABA #   ↑       ↑             
N-arachidonoyl GABA   ↑     ↓ ↑         ↓   
N-docosahexaenoyl GABA           ↑             
N-acyl glycine                         
N-palmitoyl glycine       ↑                 
N-stearoyl glycine           ↑             
N-oleoyl glycine       ↑   ↑             
N-linoleoyl glycine     ↓     ↑             
N-arachidonoyl glycine   ↑   ↑   ↑             
N-docosahexaenoyl glycine #   ↑   ↑   ↑             
Additional N-acyl amides                         
N-oleoyl leucine #                   ↑     
N-stearoyl serine  ↓                       
N-linoleoyl serine       ↑                 
N-palmitoyl threonine    ↑                     
N-palmitoyl tryptophan     ↑                   
N-stearoyl tryptophan             ↑           
N-oleoyl tyrosine           ↑             
N-arachidonoyl tyrosine             ↑           
N-palmitoyl valine   ↑                     
N- stearoyl valine     ↓                   
N-docosahexaenoyl valine #           ↑             
These are the summary data of those N-acyl amides that were significantly modified (increased or decreased) from the levels measured in the vehicle control and
do not represent all lipids tested. All averaged values for all lipids tested are shown in Supplemental Table 2. Six brain areas (STR, striatum; HIPP, hippocampus;
CER, cerebellum; THAL, thalamus; MID, midbrain; STEM, brainstem) are depicted in individual columns further separated by the treatment groups 1 hour (1H) and 3
hour (3H) post carrageenan. Those in green with an up arrow showed significant increases from control injections, whereas, those in red with down arrows showed
significant decreases from control injections p = 0.05. Those in gray are N-acyl amides that activated on of the TRPV systems tested here. #Denotes that these
compounds had not been previously identified in mammalian brain.
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Table 4 | Agonist effects of N-acyl amide mixtures on calcium
mobilization in BV-2 microglia.
N-acly amide mixtures 10 μM BV-2 Microglia
N-acyl alanine 69.48 ± 3.18
N-acyl aspartic acid 12.73±0.82
N- acyl beta-alanine 15.33±1.16
N- acyl GABA 119.56 ± 2.72
N- acyl glycine 22.91±1.32
N-acyl isoleucine 8.31±1.17
N-acyl leucine 56.47±1.62
N-acyl methionine 33.00±1.84
N-acyl phenylalanine (−)5.07 ± 2.13
N-acyl proline 102.66 ± 2.04
N-acyl serine 12.41±1.35
N-acyl threonine 12.27±1.00
N-acyl tryptophan 4.83±1.04
N-acyl tyrosine 19.74±1.24
N-acyl valine 61.33 ± 2.17
DMSO 9.09±0.84
Capsaicin (500 nM) 9.60±2.54
PAF 49.60 ± 2.71
Inonomycin 223.92 ± 5.81
Far left column lists the N-acyl amide family or control compound that was used
as the challenge compounds for each screen. Values shown are the change in
relative fluorescence units of Fura2AM from the 30 s baseline and represent the
area of the curve of analysis of 190 s post injection (see example on Figure 2.
Those values in bold black are significantly higher from those of the vehicle
injection, whereas those in bold gray are significantly lower p ≤ 0.01.
TRPV1 (Barbara et al., 2009). Therefore, the SAR of activity is
specific to the oxidation level of the same molecule. In addition,
the one antagonist that was identified here, N-docosahexaenoyl
proline, is also a long-chain fatty acid amide, providing fur-
ther evidence of the structural properties of those molecules that
successfully interact with the TRPV1 receptor. Therefore, while
our and previous data support the hypothesis that TRPV1 is an
opportunistic receptor that preferentially is activated by long-
chain, unsaturated acyl-amides, it is not activated by all of such
molecules in this category.
Similar results were seen with the identification of TRPV4
activators in that of the two N-acyl amide mixtures that were
hits for agonist activity, three individual members of each were
shown to activate the receptor. This was not the case, however,
for activity at TRPV2 and TRPV3. Wherein the N-acyl proline
mixture had the most activity at TRPV2, none of the individ-
ual members had a significant effect. While N-palmitoyl tyrosine
did have a significant effect on calcium mobilization, it was rela-
tively weak compared to the N-acyl tyrosine mixture at the same
molarity. Likewise, the N-acyl tyrosine mixture had the strongest
agonist effect at TRPV3, yet none of the individual members
showed significant activity. Intriguingly, each of these mixtures
also caused antagonist activity in the same expression systems.We
hypothesize that there are allosteric effects of individual lipids on
members of the same N-acyl amide family that would drive one
member to have a higher potency than another. This hypothesis
will be tested in future studies.
N-acyl amide activity in BV2 microglia also showed similar
patterns to those of the TRPVs tested here. 4 of the 5N-acyl amide
mixtures that caused calciummobilization in these BV2microglia
also activated different TRPVs here, with the only exception being
N-acyl alanine, which did have some activity at TRPV2, though
not at the 0.01 p-value; therefore, this was not pursued in these
studies. Further studies are aimed at determining if the N-acyl
alanines are active at additional TRPs. As mentioned previously,
however, there was not calcium mobilization with capsaicin in
these BV2 cells, suggesting that none of these responses would
be through TRPV1. Study of TRP receptor function in microglia
is a small but growing field. Although the presence of TRPV1-4
on BV-2 microglial cells has not been fully confirmed, there exists
plentiful evidence to suggest a role for TRPVs in microglial sig-
naling. Hassan and colleagues measured the rate of phagocytosis
in cultured microglial cells by quantifying the ingestion of flu-
orescently labeled latex beads. The phytocannabinoid cannabid-
iol (CBD) boosted the rate of phagocytosis, specifically, 10μM
CBD increased phagocytosis by 175% over vehicle control. BV-
2 microglia do not express the cannabinoid receptors CB1 or
CB2, thus the effect was not mediated by CB receptor signal-
ing. Pretreating with pertussis toxin, which blocks GPCRs, had
no effect on CBD’s actions, ruling out GPCR signaling pathways
as mediators of this effect. In addition to increasing phagocytosis,
CBD caused calcium influx into the microglial cells. The calcium
influx was abolished by ruthenium red, a non-selective TRP chan-
nel antagonist. Additionally, ruthenium red prevented CBD from
increasing phagocytosis. The effects on individual TRPV chan-
nels were then investigated: TRPV1 was implicated, as treatment
with capsazepine blocked the increase in phagocytosis. Without
CBD treatment, the TRPV2 agonist probenecid dose-dependently
enhanced phagocytosis in-vitro. RT-PCR revealed that TRPV2
mRNA is detectable in untreated BV-2 cells (Hassan et al., 2014).
Immunocytochemistry has shown TRPV1 to be present in rat
primary microglial cell lines. However, care must be taken in
interpreting these results as knock-out controls are not shown
and TRPV1 antibodies can produce artifactual staining. RT-PCR
showed that TRPV1 mRNA was present on rat microglia, but
not on astrocytes. Interestingly, exposure to TRPV1 agonists like
capsaicin-induced apoptosis in these cultured microglial cells.
These effects were inhibited by capsazepine, indicating a role for
TRPV1 in regulating apoptosis in microglia (Kim et al., 2006).
RT-PCR also showed TRPV1 mRNA expression in rat retinal
microglial cultures, where it may possibly have a role in regulating
intra-ocular pressure (Sappington and Calkins, 2008).
Eight out of 20 of the novel N-acyl amides identified here
as TRPV1-4 activators are conjugates of docosahexaenoic acid,
which is an omega-3 fatty acid. This is particularly interesting in
the context of the recent focus in human nutrition on this class of
lipids. Links between omega-3 fatty acids and pain associated with
inflammation have been shown and studied for decades, how-
ever, the exact molecular mechanism remains elusive (for rev see
Tokuyama and Nakamoto, 2011). Resolvin molecules are clearly
part of the answer (Ji et al., 2011); however, their rapid degra-
dation that perhaps leads to a lack of data on their endogenous
production provides a roadblock in our understanding of how
these molecules work in vivo. In our own hands, we have observed
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that N-docosahexaenoyl amides are significantly more stable and
can be readily measured in tissue. We propose that these N-
docosahexaenoyl amides may even act as more stable precursor
molecules for the more reactive and fast-lived resolvins.
Unlike the resolvin species of lipids, N-acyl amides in brain
are relatively straightforward tomeasure usingmethanolic extrac-
tions, partial purification on C18 solid phase extraction columns
and HPLC-MS/MS analysis (Bradshaw et al., 2006; Rimmerman
et al., 2008; Bradshaw et al., 2009; Smoum et al., 2010). We
recently identified 47 of those measured here in drosophila,
demonstrating that these simple bioactive lipids are not unique
to mammals or the brain (Tortoriello et al., 2013). That nearly a
third of those measured here were modified by peripheral inflam-
mation suggests that they are of the type of lipids that are rapidly
made on demand and are likely part of the myriad of signal-
ing systems that are engaged during both a stress-inducing and
painful event.
TOP–DOWN LIPIDOMICS OF N-ACYL AMIDES IN THE CNS
Carrageenan injections into the paw are a reliable model of acute
inflammation that is associated with thermal and mechanical
allodynia and hyperalgesia as well as the suite of learning a moti-
vated behaviors associated with the response to noxious stimuli
(Fecho et al., 2005). Here, we demonstrate a wide-range of reg-
ulation of N-acyl amides in six different regions of the brain;
however, we will focus our discussion on the hippocampus and
the striatum in that they showed the most dynamic changes in
N-acyl amides with peripheral inflammation. It is important to
note that they both play important and evolving roles in pain and
inflammation.
Both the striatum and hippocampus have been heavily impli-
cated as CNS regions involved in pain processing and perception
(Malow and Olson, 1981; Mcewen, 2001; Ploghaus et al., 2001;
Ferre et al., 2009; Barcelo et al., 2012), and our study confirms
that there are changes in the production of these putative N-
acyl amide signaling molecules in the striatum and hippocampus
due to inflammatory pain. However, one of the major limita-
tions of this study is the heterogeneity of these brain areas. While
both regions are discrete and easy to dissect from the brain, both
the striatum and hippocampus are also responsible for a host
of functions. The hippocampus is particularly noted for its role
in consolidation of long-term memories and spatial memory in
rodents. Constant dendritic remodeling and neurogenesis make
the hippocampus capable of learning new associations such as
avoidance behaviors to painful stimuli (Ploghaus et al., 2001).
The hippocampus is also very susceptible to glucocorticoids for
instance those released in response to a painful, stressful situation.
McEwen hypothesizes that the neurochemical and morphologi-
cal changes in the hippocampus may cause changes in chronic
pain perception (Mcewen, 2001). Indeed, patients with effectively
managed chronic pain versus those whose pain persists despite
treatment have an increased pain threshold and are able to more
sensitively discriminate between different levels of pain (Malow
and Olson, 1981).
Similarly, the striatum is involved in regulating a variety of
processes. The striatum is best known for its role in planning and
modulating motor movement by integrating sensory and motor
information. However, parts of the striatum respond exclusively
to noxious stimuli (Barcelo et al., 2012). While dopaminergic
neurons are densely expressed in the striatum and implicated
in pain processing, CB1 receptors form heteromers with D2
A2A, and μ opioid receptors indicating potential novel mech-
anisms of endocannabinoid function in the striatum beyond
retrograde signaling and inhibition of neurotransmitter release
(Ferre et al., 2009). Therefore, increases in AEA shown here
may play a role in the CB1 response as well as in the TRPV1
response.
CONCLUSIONS
These studies represent a novel direction in ion channel research
in the CNS. Blending our knowledge of lipidomics of N-acyl
amides and TRPV channel activity has allowed us to discover a
connection between the two of which the depth of has yet to be
tested. We propose that this is merely the beginning of our under-
standing of how these systems work in concert and hypothesize
that the co-evolution of N-acyl amides and ion channels plays
a major role in a wide range of cellular signaling beyond the
mammalian brain.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: http://www.frontiersin.org/journal/10.3389/fncel.2014.
00195/abstract
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